![Hyung-Ki Kim](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hyung-Ki Kim
Chief Executive Officer at CELLTRION HEALTHCARE CO., LTD.
Net worth: 26 M $ as of 2024-06-29
Profile
Currently, Hyung-Ki Kim occupies the position of Chief Executive Officer & Director at Celltrion Healthcare Co., Ltd. In the past Mr. Kim held the position of Co-Chief Executive Officer & Director at Celltrion, Inc. and Head-Strategic Planning at Daewoo Motor Co.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
CELLTRION, INC.
0.09% | 2024-06-26 | 205,618 ( 0.09% ) | 26 M $ | 2024-06-29 |
Hyung-Ki Kim active positions
Companies | Position | Start |
---|---|---|
CELLTRION HEALTHCARE CO., LTD. | Chief Executive Officer | - |
Former positions of Hyung-Ki Kim
Companies | Position | End |
---|---|---|
CELLTRION HEALTHCARE CO., LTD. | Chief Executive Officer | - |
CELLTRION, INC. | Chief Executive Officer | - |
Nexolsystem Ltd. | Director/Board Member | - |
Daewoo Motor Co.
![]() Daewoo Motor Co. Motor VehiclesConsumer Durables Part of BorgWarner, Inc., Daewoo Motor Co. is a manufacturer of automobiles. The company is based in Inchon, South Korea. | Corporate Officer/Principal | - |
CELLTRION PHARM, INC. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
CELLTRION PHARM, INC. | Health Technology |
CELLTRION, INC. | Health Technology |
Private companies | 3 |
---|---|
Nexolsystem Ltd. | |
Daewoo Motor Co.
![]() Daewoo Motor Co. Motor VehiclesConsumer Durables Part of BorgWarner, Inc., Daewoo Motor Co. is a manufacturer of automobiles. The company is based in Inchon, South Korea. | Consumer Durables |
Celltrion Healthcare Co., Ltd.
![]() Celltrion Healthcare Co., Ltd. Pharmaceuticals: MajorHealth Technology Celltrion Healthcare Co., Ltd. manufactures pharmaceutical products. Its products include infliximab, rituximab, and trastuzumab biosimilars. The company was founded on December 29, 1999 and is headquartered in Incheon, South Korea. | Health Technology |
- Stock Market
- Insiders
- Hyung-Ki Kim